Jubilant PharmovaBOM:530019 -0.40%76 ROE % is 6.73% as of Mar. 2026, which is 51% below its 10-year median of 13.64. GuruFocus rates BOM:530019 with a GF Score™ of 76/100 and a GF Value™ of ₹1,054.41 (Fairly Valued). The stock has 5 warning signs investors should review. Among 935 Drug Manufacturers companies, Jubilant Pharmova ranks worse than 50.05% on this metric.
The historical rank and industry rank for Jubilant Pharmova's ROE % or its related term are showing as below:
BOM:530019'
s ROE % Range Over the Past 10 Years
Min: -1.14 Med: 13.64 Max: 17.98
Current: 6
During the past 13 years, Jubilant Pharmova's highest ROE % was 17.98%. The lowest was -1.14%. And the median was 13.64%.
BOM:530019's ROE % is ranked worse than 50.05% of 935
companies
in the Drug Manufacturers industry
Industry Median: 6
vs BOM:530019: 6.00
Jubilant Pharmova (BOM:530019) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Jubilant Pharmova ROE % Related Terms
Jubilant Pharmova ROE % Historical Data
* Premium members only.
The historical data trend for Jubilant Pharmova's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Pharmova ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's ROE % distribution charts can be found below:
* The bar in red indicates where Jubilant Pharmova's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Jubilant Pharmova (BOM:530019) has a ROE % of 6.73% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Jubilant Pharmova and its competitors. This is 51% below median its historical median of 13.64. According to the industry distribution chart, Jubilant Pharmova ranks #468 out of 935 companies in the Drug Manufacturers industry, placing it in the top 50.1%.
Is Jubilant Pharmova's ROE % too high?
Jubilant Pharmova's current ROE % of 6.73% is 51% below median its 10-year median of 13.64. The Drug Manufacturers industry median ROE % is 6.00. Jubilant Pharmova's value of 6.73% is 12.2% above this industry median. Based on the distribution chart, Jubilant Pharmova ranks #468 out of 935 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jubilant Pharmova has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jubilant Pharmova ranks #468 out of 935 companies for ROE %. This places Jubilant Pharmova in the lower half of its industry. The industry median ROE % is 6.00. Jubilant Pharmova's value of 6.73% is 12.2% above this benchmark. While the company's 10-year median is 13.64 vs. the industry median of 6.00, Jubilant Pharmova has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jubilant Pharmova's current ROE % of 6.73% is 12.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Jubilant Pharmova and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jubilant Pharmova's current ROE % is 6.73%, which is 51% below median its own 10-year median of 13.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,054.41, compared to a current price of ₹968.75 — trading 8.1% below its estimated fair value. The current ROE % is 6.73%, which is 51% below median its 10-year median of 13.64 and 12.2% above the Drug Manufacturers industry median of 6.00. Jubilant Pharmova's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current ROE % is 6.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?
Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued.
The current stock price of ₹968.75 is trading 8.1% below its estimated GF Value™ of ₹1,054.41.
GuruFocus considers Jubilant Pharmova to be Fairly Valued.
Key valuation signals for BOM:530019:
ROE %: 6.73% (51% below median its 10-year median of 13.64)
GF Value™: ₹1,054.41 vs. price of ₹968.75 (8.1% below fair value)
Industry Position: 12.2% above the Drug Manufacturers median (#468 of 935)
No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
76GF Score
Get the complete analysis for BOM:530019
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530019 has been successfully added to your 
